PURA Confirms and Clarifies Exclusivity of Patented Cannabis Extraction Process
April 24 2020 - 1:28PM
InvestorsHub NewsWire
Dallas, TX -- April 24, 2020 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) confirms and clarifies the exclusivity of its license to
a patented cannabis extraction
process.
Earlier today the company reported on its
continuing progress in the rebranding of its recently acquired
Hemp4mula CBD confections business that includes CBD infused
gummies and gum.
The earlier release highlighted a recent
Grand View Research, Inc. report that the global CBD gummies market is expected to reach $6.94
Billion by 2025.
Puration’s rebranding strategy centers on
emphasizing the U.S. Patent and extensive university medical
research backing Puration’s gummies and
gum.
Puration has the only license of the NCM
Biotech patented extraction process and that license is exclusive
for the applications with edibles and beverages. NCM Biotech
is focused on medical research and Puration has access to that
research, but no plans to enter the pharmaceutical
market.
The benefits of the rebranded Hemp4mula
gummies and gum will be backed by NCM Biotech’s patented extraction
process and university medical research making Puration’s gummies
and gum a standout in the global
market.
See a recent research report on CBD
extracts derived from NCM Biotech’s patented extraction process:
Journal of Cannabis
Research
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Puration Inc (CE) (OTCMarkets): 0 recent articles
More Puration Inc (PK) News Articles